Clinical Trial

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 17, 2025 (before its estimated July 18, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-25.
Status change: Not Yet Recruiting → Recruiting 2025-08-12
Trial Details
NCT Number NCT06947980
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions Atopic Dermatitis
Enrollment 200 participants
Start Date 2025-06-19
Primary Completion 2026-07-18 (estimated)
Study Completion 2026-11-07 (estimated)
Updated on ClinicalTrials.gov 2025-08-17